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Introduction
Systemic reactive (AA) amyloidosis represents the most
important complication within TNF receptor associated
periodic syndrome (TRAPS), familial Mediterranean fever
(FMF) and other autoinflammatory syndromes, progres-
sively leading to endstage renal failure. The homozygous
condition of the serum amyloid A (SAA) variant SAA1.1 is
significantly associated with the occurrence of AA amyloi-
dosis in TRAPS patients. Likewise in FMF patients the
MEFV mutation c.2080A>G (M694V) correlates with amy-
loidosis and the SAA1.1/SAA1.1 genotype increases clinical
severity (age at disease onset, amyloidosis, arthritis).
Objectives
To develop a reverse-hybridization assay (Amyloidosis
StripAssay) for detection of (1) genetic markers modulat-
ing the risk of developing AA amyloidosis in TRAPS and
FMF [c.209C>T, c.224T>C (SAA1); c.2080A>G (MEFV)],
as well as (2) mannose-binding lectin 2 (MBL2) and
TNFRSF1A variants, which are suspected to be modulat-
ing factors in TRAPS [g.4447 C>G, g.4776 C>G, g.5000
C>T, c.154C>T, c.161G>A, c.170G>A (MBL2); c.473-
33C>T (TNFRSF1A)].
Methods
The Amyloidosis StripAssay is based on a multiplex PCR
and hybridization of biotinylated amplicons under exactly
defined stringency to a teststrip presenting a parallel
array of allele-specific oligonucleotide probes. Specifically
bound PCR products are detected using enzymatic colour
reaction.
Results
The specificity of the StripAssay was validated by hybri-
dizing teststrips against PCR products obtained from
plasmid clones, as well as reference DNA samples. All
genetic variants covered by the StripAssay could be unam-
biguously identified.
Conclusion
The Amyloidosis StripAssay proved to be a fast and reliable
method for detection of genetic factors modulating the risk
of developing AA amyloidosis in FMF and TRAPS. An
association between MBL2 alleles and amyloidosis is not
conclusively established, but MBL2 is of considerable diag-
nostic interest in closely related fields, including rheuma-
toid arthritis or innate immunity. Also in case of the
TNFRSF1A intron 4 polymorphism c.473-33C>T the Stri-
pAssay could be a useful tool: the c.473-33C>T variant is
involved in TNFRSF1A expression and an implication on
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